Survey to Understand Factors Contributing to Healthcare and Treatment Perceptions for Vasomotor Symptoms among Non-Hispanic/Latino Black or African American Women in the US
Gloria Richard-Davis, et al.
Prior Treatment Patterns and Healthcare Resource Utilization of Individuals Who Received Fezolinetant Treatment: A Claims Database Analysis
Barbara DePree, et al.
Vasomotor Symptoms Due to Menopause after Treatment Discontinuation in Phase 3 Fezolinetant SKYLIGHT Studies
Genevieve Neal-Perry, et al.
Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause in Participants with Medical Comorbidities: Pooled Analysis of Three 52-Week Phase 3 Studies (SKYLIGHT 1, 2, and 4)
Andrea Singer, et al.
A Matching-Adjusted Indirect Comparison of Fezolinetant and Elinzanetant for the Treatment of Vasomotor Symptoms Due to Menopause
Marla Shapiro CM, et al.
OPTION-VMS: Preliminary Analysis of a Phase 4 Observational, Real-World Study of Non-Hormonal Pharmacotherapies for Bothersome Menopause-Associated Vasomotor Symptoms
Genevieve Neal-Perry, et al.
Preliminary Analysis of Work Productivity Outcomes in OPTION-VMS: A Phase 4 Observational, Real-World Study of Non-Hormonal Treatment for Bothersome Menopause-Associated Vasomotor Symptoms
Pauline M. Maki, et al.
